{"id":"W4323307162","doi":"10.1159/000529996","title":"Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Bevacizumab; Medicine; Atezolizumab; Sorafenib; Internal medicine; Hepatocellular carcinoma; Liver function; Gastroenterology; Population; Post-hoc analysis; Oncology; Tolerability; Clinical endpoint; Surgery; Randomized controlled trial; Adverse effect; Cancer; Chemotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006293906,0.001699345,0.003157146,0.0003266509,0.0002184286,0.00126825,0.0009383985,0.0007783303,0.00262628],"category_scores_gemma":[0.004917473,0.0005724066,0.007406606,0.0004045584,0.0005677774,0.0007959901,0.0005798339,0.002384819,0.0004336154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001038022,"about_ca_system_score_gemma":0.001241373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007036434,"about_ca_topic_score_gemma":0.001717134,"domain_scores_codex":[0.9965088,0.002580898,0.0001562645,0.0003532771,0.0001779103,0.0002228225],"domain_scores_gemma":[0.9962101,0.001428593,0.0009451533,0.0005262081,0.0002349316,0.0006549665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9646084,0.00213987,0.009065394,0.0002365138,0.0108185,0.00004543018,0.00005061737,0.001342299,0.002018572,0.00005714161,0.0007180494,0.008899168],"study_design_scores_gemma":[0.5462167,0.3051417,0.1125808,0.00006965526,0.02155511,0.0002046074,0.0001117901,0.007657215,0.003551004,0.0005060774,0.002310654,0.00009468482],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950321,0.001806595,0.0006310269,0.0002826365,0.0001269312,0.0004694325,0.0009148223,0.00004457465,0.0006918991],"genre_scores_gemma":[0.9964021,0.0003438657,0.0005100992,0.0002177671,0.0001396216,0.0004177419,0.001148965,0.00002018001,0.0007997817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006293906,"threshold_uncertainty_score":0.03328574,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09168397289620757,"score_gpt":0.3275482401496349,"score_spread":0.2358642672534274,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}